
Alcohol blunts ICI efficacy, reducing TH1 CD4+ and CD8+ T cell IFN-γ production and CD8+ T cell tumor killing, while increasing the expression of TIGIT on T cells. The addition of anti-TIGIT antibodies restores anti-PD1 efficacy with alcohol.
A study shows that regular consumption of alcoholic beverages depletes the lymphocytes responsible for destroying tumors—though it also points to the potential for combination therapies to reverse this damage.
Immunotherapy has transformed the prognosis for thousands of patients with advanced tumors by teaching their own immune defenses to recognize and attack cancer. However, fewer than 30% of patients achieve a lasting response, and doctors still do not fully understand the factors that determine why the treatment succeeds in some cases but fails in others. New research has identified a common, modifiable culprit: alcohol. Regular consumption of alcoholic beverages reduces the effectiveness of immune checkpoint inhibitors—such as anti-PD-1 antibodies—by approximately half and significantly increases the risk of relapse.
The study, published in the journal Science Signaling, sheds light on a concerning clinical gap. Although oncologists typically recommend abstinence during cancer treatment, recent data from the U.S. National Institutes of Health (NIH) reveal that up to 76.4% of cancer patients continue to consume alcohol, with more than a third engaging in risky drinking patterns.
To determine exactly how alcohol interferes with this biological process, a team led by the University of North Carolina School of Medicine (USA) analyzed both experimental models—using mice with lung and bladder cancer—and the clinical records of a cohort of human patients undergoing immunotherapy.
The impact on immune defenses and survival
In the laboratory, researchers administered doses of ethanol to mice—equivalent to moderate or high human consumption (roughly three to six drinks per day)—while the animals were receiving anti-PD-1 antibodies. The results were striking: while immunotherapy significantly boosted survival in mice that consumed only water (increasing it from 22.2% to 88.9% in the bladder cancer model), alcohol effectively negated this benefit, causing survival rates to plummet below 30% and increasing the likelihood of relapse following an apparent initial recovery.
To verify whether this interference also occurs in a clinical setting, the scientists conducted a retrospective review of data from patients treated with anti-PD-1 therapy at the University of North Carolina’s cancer center between 2014 and 2018. Comparing occasional drinkers (fewer than one drink per week) with regular drinkers (averaging about eight drinks per week), they found that the latter group had lower survival rates after beginning immunotherapy—an impact that was statistically significant for lung cancer and showed a clear negative trend for bladder cancer. Regular drinkers showed a poorer survival rate after starting immunotherapy.
“This work serves as an initial resource for establishing the risk that regular alcohol consumption poses to the efficacy of immune checkpoint inhibition, and for identifying mechanisms that could be targeted for intervention,” note the authors, led by Kristen N. Gilley, a researcher at the American university.
A hostile environment within the tumor
Beyond confirming the harm, the study dissects—for the first time at a molecular level—how alcohol disarms the immune system in the face of cancer. Using single-cell RNA sequencing techniques, the scientists observed that ethanol transforms the tumor microenvironment into a hostile setting for the body’s defenses: it reduces the presence of tumor-infiltrating T lymphocytes—the elite soldiers tasked with destroying malignant cells—by more than half, while increasing the number of macrophages with an anti-inflammatory profile (which end up protecting the cancer) by over 20%.
Furthermore, alcohol compromises the quality of the lymphocytes that do manage to reach the tumor. On one hand, it blocks the production of interferon-gamma—a protein crucial for the anti-tumor response—and decimates tissue-resident memory T cells, which act as sentinels to ensure the tumor does not regrow after being eliminated. On the other hand, it induces a state of cellular exhaustion by triggering the expression of an inhibitory receptor called TIGIT. This receptor acts as an additional brake, shutting down the activity of the immune defenses even when an anti-PD-1 drug is attempting to keep them active.
A target to rescue the treatment
The discovery of this molecular brake opened an unexpected path toward salvaging the therapy. When researchers combined the standard anti-PD-1 treatment with antibodies specifically designed to block the TIGIT receptor in mice that consumed alcohol, the immunotherapy regained its full potency. The rates of complete tumor response returned to levels comparable to those seen in the abstinent animals (approximately 55.5%, versus 60% in the control group).
Despite these results, the authors urge caution regarding the direct application of these findings to human patients, given the limited size of the human cohort analyzed and the fact that alcohol consumption was self-reported—a metric that typically underestimates actual intake. Nevertheless, they advocate for the systematic inclusion of alcohol consumption data in large oncology databases, in order to assess its impact not only on immunotherapy but also on other treatment strategies that rely on a robust immune system, such as CAR-T cell therapies, chemotherapy, or radiotherapy.
Source AAAS https://www.aaas.org/

Leave a Reply